Mobile

A 12 week treatment, open-label, multicenter study to investigate the efficacy and safety of valsartan 160-320 mg with regard to effects on lipid subfractions in hypertensive patients with metabolic s...

Update Il y a 4 ans
Reference: EUCTR2005-003606-28

A 12 week treatment, open-label, multicenter study to investigate the efficacy and safety of valsartan 160-320 mg with regard to effects on lipid subfractions in hypertensive patients with metabolic syndrome

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate that valsartan 320 mg has a positive effect on small, dense LDL subfractions (LDL 5+6) in hypertensive patients with metabolic syndrome after 12 weeks of treatment.

Inclusion criteria

  • patients with hypertension and metabolic syndrome (ATP III)

Links